Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 0.76 |
| ▸ | HTR2C | P28335 | 15/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037569 | 0.94 | HTR2A (0.82) | HTR2AHTR2C | |
| SCHEMBL4538316 | 0.92 | HTR2A (0.71) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3948534 | 0.89 | HTR2A (0.70) | HTR2AHTR2CKCNH2 | |
| SCHEMBL1166585 | 0.89 | HTR2A (0.74) | HTR2AHTR2CKCNH2 | |
| SCHEMBL1865338 | 0.89 | HTR2A (0.84) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3950293 | 0.89 | HTR2A (0.67) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3948057 | 0.88 | HTR2A (0.80) | HTR2AHTR2C | |
| SCHEMBL4043306 | 0.88 | HTR2A (0.78) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3953966 | 0.87 | HTR2A (0.74) | HTR2AHTR2C | |
| SCHEMBL1165597 | 0.86 | HTR2A (1.00) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051978-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |